Send to

Choose Destination
Blood Adv. 2016 Nov 30;1(2):122-131. doi: 10.1182/bloodadvances.2016000976. eCollection 2016 Dec 13.

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

Author information

David Geffen School of Medicine at UCLA, Los Angeles, CA.
Washington University School of Medicine, St. Louis, MO.
Stanford Cancer Center, Stanford, CA.
Sarah Cannon Research Institute, Nashville, TN.
Clearview Cancer Institute, Huntsville, AL.
The University of Texas M. D. Anderson Cancer Center, Houston, TX.
Willamette Valley Cancer Institute, Springfield, OR.
Center for Cancer and Blood Disorders, Bethesda, MD.
Hofstra North Shore-LIJ School of Medicine, Hyde Park, NY.
North Star Lodge Cancer Center, Yakima, WA.
Weill Cornell Medical College, New York, NY; and.
Gilead Sciences, Foster City, CA, and Seattle, WA.


Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin lymphoma (iNHL). To evaluate the safety and activity of idelalisib in combination with immunotherapy, chemotherapy, or both, 79 patients with relapsed/refractory iNHL were enrolled based on investigator preference in 3 treatment groups. Patients received continuous idelalisib in combination with (1) rituximab (IR; 375 mg/m2 weekly × 8 doses), (2) bendamustine (IB; 90 mg/m2 per day × 2, for 6 cycles), or (3) both bendamustine and rituximab at aforementioned doses (IBR; monthly × 6 cycles). Patients had a median age of 61 years, a median of 3 prior therapies, and 46% had refractory disease. The overall response rate was 75% (22% complete response) for IR, 88% (36%) for IB, and 79% (43%) for IBR. The median progression-free survival was 37.1 months overall: 29.7 months for IR, 32.8 for IB, and 37.1 months for IBR. The median duration of response was 28.6 months in the IR group and has not been reached in the IB and IBR groups. The most common grade ≥3 adverse events and laboratory abnormalities were neutropenia (41%), pneumonia (19%), transaminase elevations (16%), diarrhea/colitis (15%), and rash (9%). The safety and efficacy reflected in these early data, however, stand in contrast with later observations of significant toxicity in subsequent phase 3 trials in frontline chronic lymphocytic leukemia and less heavily pretreated iNHL patients. Our findings highlight the limitations of phase 1 trial data in the assessment of new regimens. This trial was registered at as #NCT01088048 (an extension study was registered at as #NCT01090414).

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center